Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.05%||179.54||0.7%||$1296.44m|
|BMY||Bristol-Myers Squibb Co.||0.45%||77.59||1.0%||$1212.16m|
|MRK||Merck & Co., Inc.||-1.53%||92.32||0.7%||$1167.02m|
|LLY||Eli Lilly & Co.||2.11%||313.48||1.1%||$967.28m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.29%||142.98||0.0%||$491.89m|
|HZNP||Horizon Therapeutics Plc||2.45%||90.59||5.4%||$196.03m|
|NVO||Novo Nordisk A/S||1.30%||106.62||0.1%||$182.89m|
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProÃ¢â€žÂ¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.